Abstract: The treatment of peritoneal metastasis (PM) has been a long-standing significant challenge in clinical oncology. In the past two decades, considerable progress has been made in the diagnosis and treatment of PM, due to concerted research efforts in the field. This is characterized by the development and refinement of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). In this time, China has achieved remarkable success in PM prevention and treatment, particularly by developing new treatment methods, optimizing new technologies, cultivating groups of experts who specialize in PM, establishing nationwide academic organizations, and collaborating with international organizations such as the Peritoneal Surface Oncology Group International (PSOGI). Examples of landmark progress in China include a series of clinical studies on PM associated with gastric cancer, which have been internationally adopted as reference data; the adoption and promotion of the China-HIPEC (C-HIPEC) concept; and hosting the 12th International Congress on Peritoneal Surface Malignancies in 2021. These historical achievements have contributed to China becoming one of the international leaders in the development of treatments for PM. However, because of the large number of patients requiring effective CRS and HIPEC, the prevention and treatment of PM in China requires further development. Nationwide concerted efforts among clinical oncologists should be emphasized for further advancement in this crucial area of clinical oncology.